Magnetized viruses attack harmful bacteria

03-Aug-2017 - USA

Magnetic nanoparticle clusters have the power to punch through biofilms to reach bacteria that can foul water treatment systems, according to scientists at Rice University and the University of Science and Technology of China.

Alvarez Group/Rice University

Bacteriophages combined with nanoparticle clusters can be drawn into a biofilm with a magnet. Researchers at Rice University and the University of Science and Technology of China developed the material to kill hard-to-reach bacteria protected by biofilms in water treatment systems.

Alvarez Group/Rice University

Clusters of nanoparticles with phage viruses attached find and kill Escherichia coli bacteria in a lab test at Rice University. Researchers at Rice and the University of Science and Technology of China have developed a combination of antibacterial phages and magnetic nanoparticle clusters that infect and destroy bacteria that are usually protected by biofilms in water treatment systems.

Alvarez Group/Rice University
Alvarez Group/Rice University

The nanoclusters developed through Rice's Nanotechnology-Enabled Water Treatment (NEWT) Engineering Research Center carry bacteriophages -- viruses that infect and propagate in bacteria -- and deliver them to targets that generally resist chemical disinfection.

Without the pull of a magnetic host, these "phages" disperse in solution, largely fail to penetrate biofilms and allow bacteria to grow in solution and even corrode metal, a costly problem for water distribution systems.

The Rice lab of environmental engineer Pedro Alvarez and colleagues in China developed and tested clusters that immobilize the phages. A weak magnetic field draws them into biofilms to their targets.

"This novel approach, which arises from the convergence of nanotechnology and virology, has a great potential to treat difficult-to-eradicate biofilms in an effective manner that does not generate harmful disinfection byproducts," Alvarez said.

Biofilms can be beneficial in some wastewater treatment or industrial fermentation reactors owing to their enhanced reaction rates and resistance to exogenous stresses, said Rice graduate student and co-lead author Pingfeng Yu. "However, biofilms can be very harmful in water distribution and storage systems since they can shelter pathogenic microorganisms that pose significant public health concerns and may also contribute to corrosion and associated economic losses," he said.

The lab used phages that are polyvalent -- able to attack more than one type of bacteria -- to target lab-grown films that contained strains of Escherichia coli associated with infectious diseases and Pseudomonas aeruginosa, which is prone to antibiotic resistance.

The phages were combined with nanoclusters of carbon, sulfur and iron oxide that were further modified with amino groups. The amino coating prompted the phages to bond with the clusters head-first, which left their infectious tails exposed and able to infect bacteria.

The researchers used a relatively weak magnetic field to push the nanoclusters into the film and disrupt it. Images showed they effectively killed E. coli and P. aeruginosa over around 90 percent of the film in a test 96-well plate versus less than 40 percent in a plate with phages alone.

The researchers noted bacteria may still develop resistance to phages, but the ability to quickly disrupt biofilms would make that more difficult. Alvarez said the lab is working on phage "cocktails" that would combine multiple types of phages and/or antibiotics with the particles to inhibit resistance.

Original publication

Other news from the department science

Most read news

More news from our other portals

Last viewed contents

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Simtra BioPharma Solutions - Parsippany, USA

Simtra BioPharma Solutions - Parsippany, USA

Boehringer Ingelheim to acquire NBE-Therapeutics - Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim to acquire NBE-Therapeutics - Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

European Medicines Agency recommends that Linoladiol N and Linoladiol HN remain available - Benefits continue to outweigh risks with new restrictions

Advises on compassionate use of a new combination therapy for chronic hepatitis C - Combination of ledipasvir and sofosbuvir to be used in patients in urgent need of therapy to prevent progression of liver disease

EMA recommends approval of new treatment for platinum-resistant ovarian cancer - Vynfinit (vintafolide) offers treatment for women with limited therapeutic options; two diagnostic medicines recommended for approval will help identify patients most likely to respond

EMA endorses revised policy on handling of declarations of interests

Recommendation against combined use of medicines affecting the renin-angiotensin system